Recent studies on ER/PR-positive breast cancer tumors suggest significant anti-proliferative activity, measured by Ki67 index, of another SPRM—telapristone acetate [37,38]; however, there are no available data on its implementation in uterine leiomyoma treatment. This evidence concerns the gene MKI67 and breast carcinoma.